[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:grade-3b-follicular-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Grade 3b Follicular Lymphoma",5,1,[8,16,23,29,37],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04889716","CAR-T Followed by Bispecific Antibodies",[12],"Phase 2","RECRUITING","2026-08-26T02:19:00.742020Z","2026-07-05T05:32:16.799310Z",{"nct_id":17,"title":18,"phases":19,"status":20,"updated_at":21,"content_modified":22},"NCT07517705","MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:39.267524Z","2026-06-16T05:54:07.939905Z",{"nct_id":24,"title":25,"phases":26,"status":20,"updated_at":27,"content_modified":28},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":30,"title":31,"phases":32,"status":34,"updated_at":35,"content_modified":36},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[33],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z",{"nct_id":38,"title":39,"phases":40,"status":34,"updated_at":41,"content_modified":42},"NCT05821088","Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed\u002F Refractory Large B-Cell Lymphoma",[12],"2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.683044Z",[],[]]